NIK Controls Classical and Alternative NF-κB Activation and is Necessary for the Survival of Human T-cell Lymphoma Cells
Overview
Authors
Affiliations
Purpose: Peripheral T-cell lymphomas (PTCL) are a heterogeneous entity of neoplasms with poor prognosis, a lack of effective therapies, and a largely unknown molecular pathology. Deregulated NF-κB activity has been associated with several lymphoproliferative diseases, but its importance in T-cell lymphomagenesis is poorly understood. We investigated the function of the NF-κB-inducing kinase (NIK), in this pathway and its role as a potential molecular target in T-cell lymphomas.
Experimental Design: We used immunohistochemistry to analyze the expression of different NF-κB members in primary human PTCL samples and to study its clinical impact. With the aim of inhibiting the pathway, we used genetic silencing of NIK in several T-cell lymphoma cell lines and observed its effect on downstream targets and cell viability.
Results: We showed that the NF-κB pathway was activated in a subset of PTCLs associated with poor overall survival. NIK was overexpressed in a number of PTCL cell lines and primary samples, and a pivotal role for NIK in the survival of these tumor cells was unveiled. NIK depletion led to a dramatic induction of apoptosis in NIK-overexpressing cell lines and also showed a more pronounced effect on cell survival than inhibitor of kappa B kinase (IKK) knockdown. NIK silencing induced a blockage of both classical and alternative NF-κB activation and reduced expression of several prosurvival and antiapoptotic factors.
Conclusions: The results of the present study indicate that NIK could be a promising therapeutic target in these aggressive malignancies.
Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB.
Chen F, Qiu S, Gui A, Jiang S, Yan Y, Wu J Int J Hematol. 2024; 121(2):194-205.
PMID: 39636331 DOI: 10.1007/s12185-024-03877-y.
Lu X, Wang S, Hua X, Chen X, Zhan M, Hu Q Adv Sci (Weinh). 2023; 11(10):e2306092.
PMID: 38145335 PMC: 10933671. DOI: 10.1002/advs.202306092.
Kameda T, Shide K, Kamiunten A, Kogure Y, Morishita D, Koya J Commun Biol. 2022; 5(1):1309.
PMID: 36446869 PMC: 9709164. DOI: 10.1038/s42003-022-04284-x.
The Therapeutic Potential of Targeting NIK in B Cell Malignancies.
Haselager M, Eldering E Front Immunol. 2022; 13:930986.
PMID: 35911754 PMC: 9326486. DOI: 10.3389/fimmu.2022.930986.
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.
Lue J, OConnor O, Bertoni F Ann Lymphoma. 2021; 4:7.
PMID: 34667996 PMC: 7611845. DOI: 10.21037/aol-20-20.